Investors
Bio-manufactured materials replacing the disposable economy.
Patent-pending technology. Hospital-validated product. Currently raising our seed round.
The opportunity
A massive market with zero real alternatives.
Roughly 117 to 176 trillion single-use items annually. The vast majority is fossil-based, used for seconds, then incinerated or landfilled. No bio-manufactured alternative exists at scale.
Healthcare is the largest institutional consumer of single-use plastics. 86% of surgical consumables are single-use disposables by weight. European healthcare plastics generate 5 million tonnes of CO2 annually.
50 million per year in the Netherlands alone. 300,000 per hospital per year. All polypropylene, all incinerated. No sustainable alternative exists. This is our beachhead.
Regulatory tailwinds
EU PPWR
Packaging & Packaging Waste Regulation accelerates phase-out of fossil single-use.
PFAS bans
Regulation tightening across the EU, eliminating paper-based "alternatives."
Green Deal Healthcare
Dutch hospitals committed to 55% CO₂ reduction by 2030.
CSRD Scope 3
Large hospitals must quantify and disclose emissions from disposable procurement.
Patent-pending biofabrication.
We grow bacterial cellulose from agricultural waste at 30°C and form it into functional 3D products. Our patent-pending post-processing technology is the core IP.
Technology Readiness Level
Validation in relevant environment. Hospital pilot in progress.
Tensile strength
7 to 10x stronger than polypropylene. Waterproof, no chemical coatings.
Lower CO₂ vs polypropylene
Based on low-temperature fermentation at 30°C on agricultural waste streams.
Full biodegradation
No industrial composting required. 75% mass loss in 8 weeks under soil burial.
Patent filed 2026. Core IP: proprietary 3D cellulose forming process. Fermentation optimization protocols and strain selection procedures protected as trade secrets.
First product
Starting where it matters most.
The 30ml medical dosing cup. Used 50 million times per year in the Netherlands alone. 12 billion globally. No sustainable alternative exists.
Product specifications
- Drop-in replacement for standard polypropylene cup
- 0% PFAS, 0% microplastics
- Compatible with all standard sterilization methods (autoclave, gamma, EtO, e-beam)
- >90% drug release within 30 minutes
- FDA GRAS foundation (since 1992)
- ISO 13485 roadmap in development
Why not alternatives?
Paper cups
Contain PFAS coatings. 68 different PFAS compounds identified in paper food contact materials. Soften on contact with water.
PLA bioplastic
Requires industrial composting facilities. Does not decompose in natural conditions. Limited heat resistance.
Reusable cups
Cross-contamination risk. Washing logistics. Infection control burden. Drug residue concerns.
From lab to factory.
Founded. R&D validation.
Pre-seed closed. First hospital partner signed.
Patent filed. Pilot production 10,000 units/week. Seed round.
Semi-automated production line. 100K units/week.
Industrial scale. 1M+ units/week. Price parity with plastic.
Founded. R&D validation.
Pre-seed closed. First hospital partner signed.
Patent filed. Pilot production 10,000 units/week. Seed round.
Semi-automated production line. 100K units/week.
Industrial scale. 1M+ units/week. Price parity with plastic.
Pre-seed
Closed, 2025. Validated BC production. Completed mechanical and barrier testing. Signed first hospital partner.
Seed
Currently raising. Patent filed. Pilot production running. Funds targeted at semi-automated production line and regulatory pathway.
Long-term vision: a European biofabrication network replacing fossil disposables at industrial scale.
Four engineers. One mission.
We argue, we disagree, we push each other, because we trust each other enough to be honest. That is what it takes if we are going to change this material industry.
Supported by
Interested in the material transition?
Request our investor deck and roadmap.
We are currently raising our seed round. For our investor deck, financial model, and detailed roadmap, reach out directly.
Request investor deck